Literature DB >> 26648609

Pomalidomide.

.   

Abstract

Entities:  

Year:  2014        PMID： 26648609      PMCID： PMC4654042          DOI： 10.18773/austprescr.2015.012

Source DB:  PubMed          Journal:  Aust Prescr        ISSN： 0312-8008


× No keyword cloud information.
  2 in total

1.  Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

Authors:  Jesus San Miguel; Katja Weisel; Philippe Moreau; Martha Lacy; Kevin Song; Michel Delforge; Lionel Karlin; Hartmut Goldschmidt; Anne Banos; Albert Oriol; Adrian Alegre; Christine Chen; Michele Cavo; Laurent Garderet; Valentina Ivanova; Joaquin Martinez-Lopez; Andrew Belch; Antonio Palumbo; Stephen Schey; Pieter Sonneveld; Xin Yu; Lars Sternas; Christian Jacques; Mohamed Zaki; Meletios Dimopoulos
Journal:  Lancet Oncol       Date:  2013-09-03       Impact factor: 41.316

2.  Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.

Authors:  Paul G Richardson; David S Siegel; Ravi Vij; Craig C Hofmeister; Rachid Baz; Sundar Jagannath; Christine Chen; Sagar Lonial; Andrzej Jakubowiak; Nizar Bahlis; Kevin Song; Andrew Belch; Noopur Raje; Chaim Shustik; Suzanne Lentzsch; Martha Lacy; Joseph Mikhael; Jeffrey Matous; David Vesole; Min Chen; Mohamed H Zaki; Christian Jacques; Zhinuan Yu; Kenneth C Anderson
Journal:  Blood       Date:  2014-01-13       Impact factor: 22.113
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.